Cure My Disease

Don't miss your cure!

 Log in / Sign up

New supplement blend may rival glucosamine for knee arthritis relief

NCT ID NCT07717957

Symptom relief Sponsor: BREGO Life Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study compares Mobithron, a supplement containing hyaluronic acid, collagen, and Boswellia, to standard glucosamine for easing pain and improving function in people with knee osteoarthritis. Adults aged 50 to 75 with knee osteoarthritis take either Mobithron or glucosamine daily for three months, alongside a rehabilitation program. Researchers measure changes in pain and mobility using standard questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dietary supplement containing hyaluronic acid, undenatured type II collagen, and Boswellia serrata extract
What this could lead to
If Mobithron proves more effective than glucosamine, it could offer a new option for managing knee osteoarthritis symptoms.
What could go wrong
This is a small, early-stage study with only 34 participants, so results may not apply broadly. As a supplement, its effects may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

34 people

The number who actually took part.

Started

Jul 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 50 to 75 years. * Diagnosis of primary knee osteoarthritis. * Radiographic Kellgren-Lawrence grade II, III, or IV knee osteoarthritis. * No previous surgical intervention to the affected knee. * At least 6 months since the last intra-articular injection to the affected knee. * Able and willing to comply with the rehabilitation programme and follow-up -schedule. * Provided written informed consent. Exclusion Criteria: * History of infection involving the affected knee. * Secondary osteoarthritis (e.g., inflammatory arthritis). * Unable to comply with the rehabilitation programme or follow-up schedule. * Declined or unable to provide informed consent. * Women of child-bearing potential. * History of severe allergic reactions, including anaphylaxis. * Severe knee pain at screening (VAS ≥7). * Minimal or no knee pain at screening (VAS ≤3).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Knee osteoarthritis

Contacts and locations

Locations

  • International Islamic University Malaysia

    Kuantan, Pahang, 25200, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.